Etomidate (Synonyms: (+)-Etomidate, d-Etomidate, R 16659) |
Catalog No.GC16134 |
General anesthetic with GABA modulatory and GABA-mimetic actions
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 33125-97-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
human embryonic kidney (HEK293) cells (with high expression levels of the cloned murine 2A-adrenoceptor ,α2C-adrenoceptor and α2B -adrenoceptor subtypes) |
Preparation method |
The solubility of this compound in DMSO is >12.2mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
10μM for 20 min |
Applications |
In membranes from HEK293 cells transfected with α2-receptors, etomidate inhibited binding of the α2-antagonist, [3H]RX821002, with higher potency from α2B- and α2C-receptors than from α2A-receptors.Etomidate activated mitogen-activated protein kinase phosphorylation via α2B -receptors. In α2B-receptor–expressing HEK293 cells, stimulated with 10μM etomidate for 20 min rapidly increased phosphorylation of the extracellular signal-related kinases ERK1/2. |
Animal experiment [2]: | |
Animal models |
α2Adrenoceptor-deficient Mice, α2Bdrenoceptor-deficient Mice |
Dosage form |
intraperitoneal injection ,5–50 mg/kg body weight |
Application |
These results showed that 27% of the mice lost the reflex at 10 mg/kg etomidate and all mice transiently lost the righting reflex at 20mg/kg and higher etomidate doses. After injection of etomidate at 30 mg/kg, the righting reflex disappeared in wild-type and α2 A-deficient mice at similar times after intraperitoneal injection. On intravenous injection of etomidate at 30 mg/kg, wild-type mice showed a rapid and transient hypertensive response that was completely absent in mice lacking α2B-receptors. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Paris A, Philipp M, Tonner PH., et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. |
Etomidate(R-16659) is a GABAA receptors agonist, which is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia.Target: GABA ReceptorEtomidate is a potent inhibitor of the adrenal response to surgery. The absence of clinical consequences associated with the blunted response suggests that a major increase in adrenal hormone production may not be necessary during surgery [1]. Etomidate is an intravenous induction agent that is associated with hemodynamic stability during intubation. The agent is therefore attractive for use in critically ill patients who have a high risk of hemodynamic instability during this procedure [2]. Etomidate use was not associated with all cause 28-day mortality or hospital mortality but was associated with significantly higher ICU mortality (91% vs. 64% for etomidate and controls groups, respectively; p = 0.02). Etomidate patients who received subsequent doses of hydrocortisone required lower doses of vasopressors and had more vasopressor-free days but no improvement in mortality [3].Clinical indications: FDA Approved Date: 1983Toxicity: Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
References:
[1]. Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here Crit Care, 2012. 16(6): p. 189.
[2]. Cherfan, A.J., et al., Etomidate and mortality in cirrhotic patients with septic shock. BMC Clin Pharmacol, 2011. 11: p. 22.
[3]. Mehta, M.P., et al., Etomidate anesthesia inhibits the cortisol response to surgical stress. Acta Anaesthesiol Scand, 1985. 29(5): p. 486-9.
Cas No. | 33125-97-2 | SDF | |
Synonyms | (+)-Etomidate, d-Etomidate, R 16659 | ||
Chemical Name | ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate | ||
Canonical SMILES | CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2 | ||
Formula | C14H16N2O2 | M.Wt | 244.29 |
Solubility | ≥ 12.2mg/mL in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0935 mL | 20.4675 mL | 40.935 mL |
5 mM | 0.8187 mL | 4.0935 mL | 8.187 mL |
10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *